Levobupivacaine - Short Note for MD Anaesthesiology

Introduction & Chemistry

• Levobupivacaine is the pure S(-) enantiomer of racemic bupivacaine. Trade name: Chirocaine.
• Racemic bupivacaine is a 50:50 mixture of R(+) and S(-) enantiomers. The R(+) enantiomer is responsible for the majority of cardiotoxicity.
• It was developed specifically to exploit stereoselectivity and reduce the cardiovascular toxicity associated with racemic bupivacaine.
• Structurally, levobupivacaine differs from ropivacaine only in having a butyl (vs propyl) group on the piperidine nitrogen ring.
• Important formulation note: Levobupivacaine is formulated as a weight percentage of its free base, unlike most other local anesthetics (which are expressed as hydrochloride salts) - this must be kept in mind when comparing concentrations.

Pharmacokinetics

Mechanism of Action

• Blocks voltage-gated sodium channels in the inactivated state, preventing action potential propagation.
• Produces dose-dependent sensory and motor blockade.
• The S(-) isomer has weaker binding to cardiac Na+ channels than the R(+) isomer - the molecular basis of its reduced cardiotoxicity.

Potency Comparison

• Levobupivacaine potency is slightly less than racemic bupivacaine.
• However, the majority of clinical studies using identical doses of levobupivacaine and bupivacaine have found no significant clinical difference for spinal or epidural anesthesia.
• Compared to ropivacaine: levobupivacaine is slightly more potent (ropivacaine is ~0.6 times as potent as bupivacaine/levobupivacaine).

Available Concentrations & Clinical Uses

• Used in brachial plexus, femoral, sciatic, and other peripheral blocks.
• Suitable for continuous infusions (labour epidural, post-operative analgesia).

Key Advantage: Reduced Cardiotoxicity

1. Animal models show levobupivacaine and ropivacaine exhibit 30-40% less cardiovascular toxicity than bupivacaine mg-for-mg (Barash).
2. In human studies, this difference appears less striking than in animals but still clinically meaningful.
3. Electrophysiological studies on isolated cardiac tissue confirm that S(-)-bupivacaine is less potent than R(+)-bupivacaine in:
   • Blocking the cardiac action potential
   • Binding voltage-gated sodium channels during the inactivated stage
4. The R(+) isomer causes much slower recovery of Na+ channel blockade after a cardiac action potential (the hallmark of bupivacaine cardiotoxicity). The S(-) isomer shows faster recovery.
5. Epidurally, levobupivacaine has the same clinical characteristics as bupivacaine but is less cardiotoxic.
6. The reduced cardiotoxicity is more theoretical than a real risk in spinal anesthesia (due to the very small doses used), but it matters most when large volumes are used (epidural, peripheral blocks).

CNS Toxicity

• Levobupivacaine, like all potent long-acting agents (bupivacaine, ropivacaine), can cause CNS excitation leading to seizures at high plasma concentrations.
• CNS toxicity threshold is lower than cardiovascular toxicity threshold.
• Toxic plasma levels (from Barash): CNS effects begin at 5-10 mcg/mL (lightheadedness, tinnitus, tongue numbness); seizures/unconsciousness at 10-15 mcg/mL; cardiac depression at >25 mcg/mL.
• Hypercapnia, acidosis, and hypoxia (e.g., following a seizure) potentiate cardiotoxicity - a dangerous positive feedback.

Comparison Table: Levobupivacaine vs Bupivacaine vs Ropivacaine

Key Exam Points (Summary)

1. Pure S(-) enantiomer of bupivacaine; trade name Chirocaine.
2. Developed to reduce cardiotoxicity of racemic bupivacaine.
3. Same clinical profile as bupivacaine at equal doses (same onset, duration, sensory/motor block).
4. 30-40% less cardiotoxic than bupivacaine in animal models; difference less clear in humans.
5. Epidural: 0.5-0.75% for surgery; 0.125-0.25% for analgesia.
6. Formulated as free base (not hydrochloride salt) - adjust comparisons accordingly.
7. S(-) enantiomers are metabolized more slowly - risk of accumulation with prolonged infusions.
8. The reduced cardiotoxicity advantage is most relevant with large-volume peripheral nerve blocks and epidural anesthesia, not spinal (where doses are tiny).
9. Ropivacaine also offers similar cardiotoxicity reduction but is less potent per mg.